Reply
- PMID: 34605229
- DOI: 10.1002/art.41991
Reply
Comment on
-
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Arthritis Rheumatol. 2021 Aug;73(8):1366-1383. doi: 10.1002/art.41773. Epub 2021 Jul 8. Arthritis Rheumatol. 2021. PMID: 34235894 Free PMC article.
-
Rituximab versus cyclophosphamide for remission induction in active, severe antineutrophil cytoplasmic antibody-associated vasculitis: comment on the article by Chung et al.Arthritis Rheumatol. 2022 Mar;74(3):544-545. doi: 10.1002/art.42002. Epub 2022 Jan 18. Arthritis Rheumatol. 2022. PMID: 34694068 No abstract available.
References
-
- De Groot K, Harper L, Jayne DR, Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80.
-
- Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012;71:955-60.
-
- Clowse ME, Copland SC, Hsieh TC, Chow SC, Hoffman GS, Merkel PA, et al. Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken) 2011;63:1777-81.
-
- Fauci AS, Dale DC, Wolff SM. Cyclophosphamide and lymphocyte subpopulations in Wegener's granulomatosis. Arthritis Rheum 1974;17:355-61.
-
- Cupps TR, Edgar LC, Fauci AS. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 1982;128:2453-7.
Publication types
LinkOut - more resources
Full Text Sources
